

Ravi Vij

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1818604/publications.pdf>

Version: 2024-02-01

324
papers

10,906
citations

61687

45
h-index

42259

96
g-index

326
all docs

326
docs citations

326
times ranked

13872
citing authors

#	ARTICLE	IF	CITATIONS
1	The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160.	1.7	10
2	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.2	11
3	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	3.4	32
4	Ablation of VLA4 in multiple myeloma cells redirects tumor spread and prolongs survival. <i>Scientific Reports</i> , 2022, 12, 30.	1.6	12
5	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	3.3	81
6	CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells. <i>Leukemia</i> , 2022, 36, 1625-1634.	3.3	15
7	Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8031-8031.	0.8	1
8	Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8055-8055.	0.8	3
9	Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in <sc>MAMMOTH</sc>. <i>American Journal of Hematology</i> , 2021, 96, E5-E8.	2.0	20
10	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
11	Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world". <i>Annals of Hematology</i> , 2021, 100, 1261-1266.	0.8	7
12	A phase I trial evaluating the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1441-1449.	0.6	2
13	Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy. <i>Leukemia</i> , 2021, 35, 2346-2357.	3.3	28
14	Autologous stem cell transplant for patients with multiple myeloma between ages 75 and 78. <i>Bone Marrow Transplantation</i> , 2021, 56, 2016-2018.	1.3	2
15	Co-evolution of tumor and immune cells during progression of multiple myeloma. <i>Nature Communications</i> , 2021, 12, 2559.	5.8	68
16	LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving 3 prior lines of therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8041-8041.	0.8	6
17	A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3043-3046.	0.6	1
18	Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions. <i>JCO Oncology Practice</i> , 2021, 17, 415-418.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). <i>Blood Advances</i> , 2021, 5, 2775-2787.	2.5	15
20	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 19343.	1.6	6
21	Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. <i>BMC Cancer</i> , 2021, 21, 993.	1.1	8
22	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. <i>JCO Precision Oncology</i> , 2021, 5, 191-203.	1.5	4
23	VLA4-Targeted Nanoparticles Hijack Cell Adhesion-Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival. <i>Clinical Cancer Research</i> , 2021, 27, 1974-1986.	3.2	17
24	3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2690-2690.	0.6	0
25	LocoMMotion: A Prospective, Non-Interventional, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma Who Received ≥3 Prior Lines of Therapy. <i>Blood</i> , 2021, 138, 3057-3057.	0.6	1
26	Financial Toxicity Among Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 4027-4027.	0.6	2
27	A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 900-900.	0.6	36
28	Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2021, 138, 2691-2691.	0.6	0
29	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq1 1 0.784314 rgBT /Over	0.6	1
30	Cost differential associated with hospice use among older patients with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 88-92.	0.5	7
31	Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1188-1190.	1.3	1
32	Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database. <i>Cancer</i> , 2020, 126, 808-813.	2.0	23
33	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	0.6	6
34	Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 6037.	5.8	51
35	Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. <i>Blood</i> , 2020, 136, 2513-2523.	0.6	56
36	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14

#	ARTICLE	IF	CITATIONS
37	A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. <i>Leukemia</i> , 2020, 34, 3298-3309.	3.3	37
38	Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338.	1.7	23
39	Evolution and structure of clinically relevant gene fusions in multiple myeloma. <i>Nature Communications</i> , 2020, 11, 2666.	5.8	31
40	Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States. <i>JCO Oncology Practice</i> , 2020, 16, e1169-e1180.	1.4	8
41	Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia. <i>Haematologica</i> , 2020, 105, e404-e407.	1.7	16
42	Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 647-651.	0.2	15
43	The characteristics, treatment patterns, and outcomes of older adults aged 80 and over with multiple myeloma. <i>Journal of Geriatric Oncology</i> , 2020, 11, 1274-1278.	0.5	12
44	DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. <i>Annals of Hematology</i> , 2020, 99, 1041-1048.	0.8	12
45	The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1137-1143.	2.0	13
46	First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 2308-2317.	3.2	20
47	Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1414-1424.	2.0	5
48	Newly Diagnosed Myeloma in 2020. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e144-e158.	1.8	9
49	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
50	A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTEA® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). <i>Blood</i> , 2020, 136, 28-29.	0.6	83
51	Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 43-44.	0.6	44
52	A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. <i>Blood Advances</i> , 2020, 4, 181-190.	2.5	16
53	Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Compass Study. <i>Blood</i> , 2020, 136, 28-29.	0.6	2
54	Myeloma Cell Associated Therapeutic Protein Discovery Using Single Cell RNA-Seq Data. <i>Blood</i> , 2020, 136, 4-5.	0.6	0

#	ARTICLE	IF	CITATIONS
55	A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma. <i>Blood</i> , 2020, 136, 31-32.	0.6	0
56	Inhibition of HIF-1a By PX-478 Normalizes Blood Vessels, Improves Drug Delivery and Suppresses Progression and Dissemination in Multiple Myeloma. <i>Blood</i> , 2020, 136, 3-3.	0.6	3
57	A Phase I Study of FT538, a First-of-Kind, Off-the-Shelf, Multiplexed Engineered, iPSC-Derived NK Cell Therapy As Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Daratumumab or Elotuzumab in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2020, 136, 3-3.	0.6	4
58	D-Dimer Improves Risk Prediction of Venous Thromboembolism in Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 26-27.	0.6	2
59	A Preliminary Assessment of Heterozygous CFHR3-CFHR1 Deletion As a Permissive Mutation in Carfilzomib-Induced Atypical Hemolytic Uremic Syndrome. <i>Blood</i> , 2020, 136, 8-9.	0.6	0
60	Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center ScRNA-Seq Data. <i>Blood</i> , 2020, 136, 15-15.	0.6	0
61	Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center ScRNA-Seq Study. <i>Blood</i> , 2020, 136, 6-8.	0.6	0
62	Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases. <i>Leukemia and Lymphoma</i> , 2019, 60, 471-476.	0.6	13
63	Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients. <i>Leukemia and Lymphoma</i> , 2019, 60, 118-123.	0.6	23
64	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
65	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.	0.6	11
66	Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. <i>New England Journal of Medicine</i> , 2019, 381, 727-738.	13.9	460
67	A Mixed-Methods Study of Stem Cell Transplantation Utilization for Newly Diagnosed Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e521-e525.	0.2	4
68	EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 744-750.	0.2	7
69	Next Generation Sequencing-based Validation of the Revised International Staging System for Multiple Myeloma: An Analysis of the MMRF CoMMpass Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 285-289.	0.2	17
70	A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1984-1992.	2.0	25
71	A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e588-e593.	0.2	6
72	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2019, 25, 4907-4916.	3.2	36

#	ARTICLE	IF	CITATIONS
73	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
74	Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. <i>Leukemia</i> , 2019, 33, 2266-2275.	3.3	385
75	A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2019, 25, 3776-3783.	3.2	14
76	Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-183. <i>British Journal of Haematology</i> , 2019, 186, e41-e44.	1.2	59
77	Allogeneic transplantation in elderly patients ≥ 65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
78	Health related quality of life for multiple myeloma patients according to treatment strategy after autologous stem cell transplant: a cross-sectional study using EORTC, EQ-5D and MY-20 scales. <i>Leukemia and Lymphoma</i> , 2019, 60, 1275-1282.	0.6	7
79	Geriatric Assessment in Older Adults with Multiple Myeloma. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 987-991.	1.3	42
80	Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study. <i>Blood</i> , 2019, 134, 2190-2190.	0.6	1
81	Dramatic Resolution of HLH after Treatment with the JAK 1/2 Inhibitor, Ruxolitinib. <i>Blood</i> , 2019, 134, 2325-2325.	0.6	1
82	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. <i>Blood</i> , 2019, 134, 602-602.	0.6	10
83	Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages. <i>Blood</i> , 2019, 134, 364-364.	0.6	0
84	Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019, 134, 5701-5701.	0.6	0
85	Blocking JAK1/JAK2 While Sparing JAK3 Not Only Prevents GvHD but Also Promotes Damaged Tissue Repair. <i>Blood</i> , 2019, 134, 4420-4420.	0.6	0
86	Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. <i>Cell Reports</i> , 2018, 23, 227-238.e3.	2.9	407
87	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
88	Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results. <i>British Journal of Haematology</i> , 2018, 180, 821-830.	1.2	32
89	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	1.3	1
90	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. <i>Nature Communications</i> , 2018, 9, 455.	5.8	150

#	ARTICLE	IF	CITATIONS
91	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. <i>Haematologica</i> , 2018, 103, e270-e273.	1.7	1
92	Preclinical Development of CD38-Targeted [⁸⁹ Zr]Zr-DFO-Daratumumab for Imaging Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 216-222.	2.8	50
93	Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, 101-106.	1.7	18
94	Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies. <i>Oncologist</i> , 2018, 23, 159-170.	1.9	27
95	Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2018, 36, 859-866.	0.8	140
96	Bones in Multiple Myeloma: Imaging and Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 638-646.	1.8	30
97	Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study. <i>Annals of Hematology</i> , 2018, 97, 2455-2463.	0.8	16
98	The efficacy of salvage autologous stem cell transplant among patients with multiple myeloma who received maintenance therapy post initial transplant. <i>Bone Marrow Transplantation</i> , 2018, 53, 1483-1486.	1.3	12
99	Multiple Myeloma Patients Ineligible for Randomized Controlled Trials Have Poorer Outcomes Irrespective of Treatment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e363-e364.	0.2	4
100	A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. <i>Blood Cancer Journal</i> , 2018, 8, 35.	2.8	41
101	Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 155-155.	0.6	21
102	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. <i>Blood</i> , 2018, 132, 123-123.	0.6	6
103	Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database. <i>Blood</i> , 2018, 132, 3284-3284.	0.6	1
104	Subsequent Treatment Outcomes of Multiple Myeloma Refractory to CD38-Monoclonal Antibody Therapy. <i>Blood</i> , 2018, 132, 2015-2015.	0.6	10
105	Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study. <i>Blood</i> , 2018, 132, 5666-5666.	0.6	1
106	D.C.E.P. in Patients with Quad- or Penta-Refractory Multiple Myeloma. <i>Blood</i> , 2018, 132, 2021-2021.	0.6	1
107	Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study. <i>Blood</i> , 2018, 132, 1991-1991.	0.6	0
108	Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study. <i>Blood</i> , 2018, 132, 3285-3285.	0.6	0

#	ARTICLE	IF	CITATIONS
109	The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma. Blood, 2018, 132, 4463-4463.	0.6	0
110	Disparities in Healthcare Resource Utilization for Multiple Myeloma. Blood, 2018, 132, 4793-4793.	0.6	1
111	3D-Tissue Engineered Bone Marrow (3DTEBM) Culture Retrospectively Predicts Treatment Clinical Outcomes of Multiple Myeloma Patients. Blood, 2018, 132, 1987-1987.	0.6	0
112	Characterization of Germline Variants in Multiple Myeloma. Blood, 2018, 132, 4499-4499.	0.6	0
113	Bendamustine in Patients with Quad- and Penta-Refractory Multiple Myeloma. Blood, 2018, 132, 5627-5627.	0.6	1
114	The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients. Blood, 2018, 132, 3439-3439.	0.6	0
115	Comprehensive Multi-Omics Analysis of Gene Fusions in a Large Multiple Myeloma Cohort. Blood, 2018, 132, 1898-1898.	0.6	0
116	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 rgt /Overlock 10 Tf 5	0.6	0
117	Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. Leukemia and Lymphoma, 2017, 58, 1872-1879.	0.6	50
118	T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653.	2.0	38
119	Treating Multiple Myeloma Patients With Oral Therapies. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 243-251.	0.2	30
120	A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood, 2017, 129, 3294-3303.	0.6	155
121	Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colonyâ€“Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Biology of Blood and Marrow Transplantation, 2017, 23, 1282-1289.	2.0	5
122	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	2.0	45
123	Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft. Blood, 2017, 129, 2680-2692.	0.6	66
124	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	1.7	79
125	Population Pharmacokinetics and Exposureâ€“Response Relationship of Carfilzomib in Patients With Multiple Myeloma. Journal of Clinical Pharmacology, 2017, 57, 663-677.	1.0	10
126	Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 2017, 130, 2401-2409.	0.6	403

#	ARTICLE	IF	CITATIONS
127	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	2.2	132
128	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2199-2204.	2.0	7
129	Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study. <i>Annals of Hematology</i> , 2017, 96, 1693-1698.	0.8	7
130	Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2065-2069.	2.0	19
131	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1736-1743.	2.0	44
132	Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 555-562.	0.2	28
133	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
134	Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-8.	1.0	12
135	CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. <i>Journal of Clinical Investigation</i> , 2017, 127, 4042-4058.	3.9	236
136	A phase Ib study of atezolizumab (atezo) alone or in combination with lenalidomide or pomalidomide and/or daratumumab in patients (pts) with multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8053-TPS8053.	0.8	3
137	Race Is Associated with Bortezomib but Not Lenalidomide Utilization during First-Line Treatment of Multiple Myeloma. <i>Blood</i> , 2017, 130, 862-862.	0.6	0
138	Proteasome inhibitor associated thrombotic microangiopathy. <i>American Journal of Hematology</i> , 2016, 91, E348-52.	2.0	95
139	<sc>TAK-228 (formerly <sc>MLN0128), an investigational oral dual <sc>TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2016, 91, 400-405.	2.0	89
140	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	2.0	83
141	A <sc>CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma. <i>British Journal of Haematology</i> , 2016, 173, 70-81.	1.2	20
142	Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1324-1329.	2.0	35
143	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1696-1701.	2.0	50
144	A study of high-dose lenalidomide induction and low-dose lenalidomide maintenance therapy for patients with hypomethylating agent refractory myelodysplastic syndrome. <i>Leukemia and Lymphoma</i> , 2016, 57, 2535-2540.	0.6	11

#	ARTICLE	IF	CITATIONS
145	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1609-1618.	1.1	18
146	Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation. <i>Leukemia Research</i> , 2016, 49, 1-6.	0.4	31
147	Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay. <i>British Journal of Haematology</i> , 2016, 173, 884-895.	1.2	29
148	Clonal Evolution in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S130-S134.	0.2	21
149	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	13.9	663
150	Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2155-2158.	2.0	8
151	Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1851-1860.	2.0	135
152	Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 129-138.	0.2	68
153	A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 728-730.	0.6	14
154	New Approaches to Molecular Imaging of Multiple Myeloma. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1-4.	2.8	39
155	A phase I study of thymoglobulin for relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2016, 57, 453-455.	0.6	0
156	Molecular Predictors of Outcome and Drug Response in Multiple Myeloma: An Interim Analysis of the Mmr CoMMpass Study. <i>Blood</i> , 2016, 128, 194-194.	0.6	12
157	Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2110-2110.	0.6	20
158	HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS). <i>Blood</i> , 2016, 128, 3250-3250.	0.6	1
159	The Efficacy of Salvage Autologous Stem Cell Transplant for Patients with Multiple Myeloma Who Received Maintenance Therapy Following Initial Transplant. <i>Blood</i> , 2016, 128, 3563-3563.	0.6	2
160	Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study. <i>Blood</i> , 2016, 128, 491-491.	0.6	21
161	Imaging of Plasma Cell Dyscrasias with FDG-PET/MRI: A Single-Center Experience. <i>Blood</i> , 2016, 128, 5611-5611.	0.6	1
162	Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2016, 128, 675-675.	0.6	38

#	ARTICLE	IF	CITATIONS
163	Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 - StAMINA Trial). <i>Blood</i> , 2016, 128, LBA-1 LBA-1.	0.6	52
164	Health care resource utilization (HCRU) in relapsed/refractory multiple myeloma (RRMM): Results from PREAMBLE.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6621-6621.	0.8	1
165	Phase I venetoclax monotherapy for relapsed/refractory multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 8032-8032.	0.8	7
166	Next Generation Sequencing Based Revised International Staging System (R-ISS) for Multiple Myeloma. <i>Blood</i> , 2016, 128, 2349-2349.	0.6	0
167	An Ongoing, Observational Cohort Study in Multiple Myeloma (PREAMBLE): Preliminary Efficacy Analyses in Patients with 1 Line of Prior Therapy. <i>Blood</i> , 2016, 128, 2403-2403.	0.6	5
168	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. <i>Blood</i> , 2016, 128, 4658-4658.	0.6	0
169	Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 680-686.	0.2	6
170	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	0.6	565
171	Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. <i>PLoS ONE</i> , 2015, 10, e0127828.	1.1	26
172	Targeted treatments for multiple myeloma: specific role of carfilzomib. <i>Pharmacogenomics and Personalized Medicine</i> , 2015, 8, 23.	0.4	13
173	Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2959-2961.	0.6	2
174	Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1bâ€”2 dose-escalation study. <i>Lancet Haematology</i> ,the, 2015, 2, e516-e527.	2.2	140
175	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
176	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
177	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1425-1430.	2.0	12
178	Personalization of cancer treatment using predictive simulation. <i>Journal of Translational Medicine</i> , 2015, 13, 43.	1.8	23
179	Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2643-2649.	0.6	47
180	Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. <i>Journal of Clinical Oncology</i> , 2015, 33, 4167-4175.	0.8	149

#	ARTICLE	IF	CITATIONS
181	Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 3320-3328.	0.6	67
182	Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1761-1769.	2.0	143
183	Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1153-1154.	2.0	14
184	3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. <i>Biomaterials</i> , 2015, 73, 70-84.	5.7	120
185	Impact of Pretransplant Therapy and Depth of Disease Response before Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 335-341.	2.0	64
186	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59.	2.0	34
187	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival. <i>Blood</i> , 2015, 126, 2093-2093.	0.6	1
188	Safety and Efficacy of Venetoclax (ABT-199/GDC-0199) Monotherapy for Relapsed/Refractory Multiple Myeloma: Phase 1 Preliminary Results. <i>Blood</i> , 2015, 126, 4219-4219.	0.6	11
189	A Randomized Trial of Tbo-Filgrastim Versus Filgrastim for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma or Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 516-516.	0.6	3
190	Synchronous and metachronous second malignancies in multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2015, 33, e19535-e19535.	0.8	1
191	Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. <i>FASEB Journal</i> , 2015, 29, 926.9.	0.2	0
192	A Second Generation, Multiple Myeloma-Specific, Targeted Sequencing Platform for Detecting Translocations, Copy Number Alterations, and Single Nucleotide Variants. <i>Blood</i> , 2015, 126, 4207-4207.	0.6	0
193	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2015, 126, 3144-3144.	0.6	0
194	Phase II Study of Propylene Glycol-Free Melphalan (Evomela) Combined with Carmustine, Etoposide, and Cytarabine (BEAM) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3196-3196.	0.6	0
195	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. <i>PLoS Computational Biology</i> , 2014, 10, e1003665.	1.5	400
196	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 46-52.	2.0	86
197	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
198	Allotransplantation for Patients Age \geq 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37

#	ARTICLE	IF	CITATIONS
199	Deep Sequencing Reveals Myeloma Cells in Peripheral Blood in Majority of Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 131-139.e1.	0.2	54
200	Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4. <i>Cancer Cell</i> , 2014, 25, 530-542.	7.7	40
201	Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. <i>Haematologica</i> , 2014, 99, e162-e164.	1.7	39
202	Geriatric Assessment in Older Adults with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2014, 124, 1286-1286.	0.6	2
203	Pharmacokinetics and Safety of Elotuzumab in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma and Various Levels of Renal Function: Results of a Phase 1b Study. <i>Blood</i> , 2014, 124, 2119-2119.	0.6	2
204	Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010). <i>Blood</i> , 2014, 124, 2134-2134.	0.6	4
205	Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts). <i>Blood</i> , 2014, 124, 2141-2141.	0.6	6
206	Therapy Personalization Using Predictive Simulation Approach with Ex-Vivo Clinical Validations. <i>Blood</i> , 2014, 124, 2232-2232.	0.6	1
207	Acute Myeloid Leukemia Patients with Pre-Transplant Ablated Marrows Have Similar Rates of Survival and Relapse Compared to Patients in Complete Remission after Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2557-2557.	0.6	1
208	Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results. <i>Blood</i> , 2014, 124, 31-31.	0.6	11
209	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. <i>Blood</i> , 2014, 124, 34-34.	0.6	21
210	CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a "test dose" Strategy to Target Busulfan Exposure. <i>Blood</i> , 2014, 124, 543-543.	0.6	6
211	Treatment Advances for Multiple Myeloma Have Disproportionally Benefited Patients Who Are Young, White, and Have Higher Socioeconomic Status. <i>Blood</i> , 2014, 124, 555-555.	0.6	24
212	Survival after T-Cell Replete Haplo-Identical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 679-679.	0.6	8
213	A Phase 1b Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 83-83.	0.6	19
214	A Study of High Dose Lenalidomide Induction and Low Dose Lenalidomide Maintenance for Patients with Hypomethylating Agent Refractory MDS. <i>Blood</i> , 2014, 124, 1931-1931.	0.6	4
215	Inherited Loss of Samsn1 Contributes to Increased Risk of MGUS and MM through Effects on Multiple Cell Types, Including B-Cells, Transformed Myeloma Cells, and Macrophages. <i>Blood</i> , 2014, 124, 2075-2075.	0.6	0
216	Patient-Derived 3D Tissue-Engineered Bone Marrow Cultures Support Primary MM Growth. <i>Blood</i> , 2014, 124, 4705-4705.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 2456-2456.	0.6	1
218	An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Initial Assessment of Treatment Patterns in Patients with ≥6 Months Follow-up. <i>Blood</i> , 2014, 124, 1297-1297.	0.6	0
219	CD138-Independent Strategy for Detecting Residual and Circulating Myeloma Plasma Cells. <i>Blood</i> , 2014, 124, 2077-2077.	0.6	0
220	3D Tissue-Engineered Bone Marrow Cultures Induce Drug Resistance, De-Differentiation and Cytokine Expression Changes in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2069-2069.	0.6	0
221	Front-Line Radiotherapy Is Associated with Shortened Survival in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2014, 124, 5696-5696.	0.6	0
222	Impact of Remission Status on Outcomes in AML Patients ≥ 60 Years of Age after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 1263-1263.	0.6	0
223	Chemotherapy Versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplant: A Retrospective Review. <i>Blood</i> , 2014, 124, 3944-3944.	0.6	0
224	A Phase I Study of Carfilzomib for Relapsed or Refractory Acute Myeloid and Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 5292-5292.	0.6	0
225	A Phase I Study of Carfilzomib and Pegylated Liposomal Doxorubicin for Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2014, 124, 4731-4731.	0.6	0
226	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. <i>Blood</i> , 2014, 124, 850-850.	0.6	0
227	A step before the next leap?. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 610-612.	12.5	0
228	Tumor Hypoxia Promotes Dissemination and Tumor Colonization In Waldenström Macroglobulinemia. <i>Blood</i> , 2013, 122, 3011-3011.	0.6	1
229	Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM). <i>Blood</i> , 2013, 122, 3220-3220.	0.6	12
230	Interim Analysis Of The MmrF Compass Trial, a Longitudinal Study In Multiple Myeloma Relating Clinical Outcomes To Genomic and Immunophenotypic Profiles. <i>Blood</i> , 2013, 122, 532-532.	0.6	34
231	A Phase II Study Of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) As Conditioning Regimen Prior To Second Autologous Stem Cell Transplantation For Multiple Myeloma. <i>Blood</i> , 2013, 122, 5492-5492.	0.6	3
232	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. <i>Blood</i> , 2013, 122, 3931-3931.	0.6	0
233	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. <i>Blood</i> , 2013, 122, 2816-2816.	0.6	0
234	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). <i>Blood</i> , 2013, 122, 3185-3185.	0.6	0

#	ARTICLE	IF	CITATIONS
235	A New Multinational Observational Study In Multiple Myeloma: Initial Report Of The PREAMBLE Study. Blood, 2013, 122, 1964-1964.	0.6	1
236	Hypoxia Induces Drug Resistance In Multiple Myeloma. Blood, 2013, 122, 1852-1852.	0.6	2
237	An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood, 2012, 119, 5661-5670.	0.6	235
238	An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. British Journal of Haematology, 2012, 158, 739-748.	1.2	157
239	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. New England Journal of Medicine, 2012, 366, 1770-1781.	13.9	1,024
240	Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. Blood, 2012, 120, 1859-1859.	0.6	1
241	A Phase 2 Study of Elotuzumab (Elo) in Combination with Lenalidomide and Low-Dose Dexamethasone (Ld) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (R/R MM): Updated Results. Blood, 2012, 120, 202-202.	0.6	16
242	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. Blood, 2012, 120, 4070-4070.	0.6	1
243	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. Blood, 2012, 120, 450-450.	0.6	11
244	Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT).. Journal of Clinical Oncology, 2012, 30, 8016-8016.	0.8	11
245	A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2012, 30, 8020-8020.	0.8	2
246	Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1.. Journal of Clinical Oncology, 2012, 30, 8035-8035.	0.8	1
247	Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).. Journal of Clinical Oncology, 2012, 30, 8011-8011.	0.8	0
248	A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).. Journal of Clinical Oncology, 2012, 30, TPS8114-TPS8114.	0.8	0
249	Autologous stem cell transplant in older patients with multiple myeloma (MM): Analysis of the nationwide inpatient sample (NIS).. Journal of Clinical Oncology, 2012, 30, e18551-e18551.	0.8	0
250	Pre-Transplant Salvage Therapy Prior to Autologous Transplant (AHCT) in Patients Not Responding to Initial Induction for Multiple Myeloma (MM). Blood, 2012, 120, 597-597.	0.6	0
251	Rb Protects B-Lineage Hematopoietic Progenitor Cells From Oxidative Stress and Exhaustion. Blood, 2012, 120, 1315-1315.	0.6	0
252	Carfilzomib in multiple myeloma. Clinical Advances in Hematology and Oncology, 2012, 10, 591-3.	0.3	2

#	ARTICLE	IF	CITATIONS
253	Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis. Blood, 2011, 118, 1876-1876.	0.6	13
254	Multivariate Modelling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib. Blood, 2011, 118, 1877-1877.	0.6	10
255	Epoxyketone-Based Proteasome Inhibitors Carfilzomib and Orally Bioavailable ONX 0912 Have Anti-Resorptive and Bone-Anabolic Activity in Addition to Anti-Myeloma Effects. Blood, 2011, 118, 2906-2906.	0.6	11
256	A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 303-303.	0.6	8
257	Comorbidities Influence Survival in Patients with Multiple Myeloma. Blood, 2011, 118, 3142-3142.	0.6	1
258	Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in High-Risk and/or Stage 23 Relapsed and/or Refractory Multiple Myeloma: A Retrospective Subset Analysis of the Phase 2 Study,. Blood, 2011, 118, 3968-3968.	0.6	1
259	The Speed of Response to Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma: An Exploratory Analysis of Results From 2 Multicenter Phase 2 Clinical Trials,. Blood, 2011, 118, 3969-3969.	0.6	6
260	Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM). Blood, 2011, 118, 631-631.	0.6	6
261	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. Blood, 2011, 118, 634-634.	0.6	9
262	Final Results From the Bortezomib-naïve Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory MM. Blood, 2011, 118, 813-813.	0.6	4
263	Phase I Study of Oral Clofarabine Consolidation in Adults Aged 60 and Older with Acute Myeloid Leukemia,. Blood, 2011, 118, 3633-3633.	0.6	0
264	A Phase 1 Study of Concomitant High Dose Lenalidomide and 5-Azacytidine Induction in the Treatment of Acute Myeloid Leukemia,. Blood, 2011, 118, 3616-3616.	0.6	1
265	Genomic Landscape of Immunoglobulin Light Chain (AL) Amyloidosis and Comparative Analyses with Related Malignant Plasma Cell Disorder- Multiple Myeloma. Blood, 2011, 118, 809-809.	0.6	0
266	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. Blood, 2011, 118, 1024-1024.	0.6	0
267	Phase I Study of Cladribine (2-chlorodeoxyadenosine), Cytarabine and G-CSF Based Induction Therapy (CLAG) with ATRA (All-trans retinoic acid) and Midostaurin for Relapsed/Refractory AML,. Blood, 2011, 118, 3609-3609.	0.6	0
268	High Throughput Digital Quantification of Genomic Copy Number Alterations in Multiple Myeloma. Blood, 2011, 118, 1830-1830.	0.6	0
269	Phase I Study of Panobinostat Plus Decitabine In Elderly Patients with Advanced MDS or AML.. Blood, 2010, 116, 1060-1060.	0.6	10
270	Decitabine for Older AML Patients: An Effective Therapy Associated with Short Hospitalization and No Invasive Fungal Infection.. Blood, 2010, 116, 1063-1063.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study. <i>Blood</i> , 2010, 116, 1936-1936.	0.6	2
272	Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010, 116, 1953-1953.	0.6	4
273	Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 1954-1954.	0.6	6
274	A Phase I Dose-Escalation Study of Combination Decitabine, Arsenic Trioxide and Ascorbic Acid In Patients with MDS and AML. <i>Blood</i> , 2010, 116, 2148-2148.	0.6	1
275	Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM). <i>Blood</i> , 2010, 116, 3031-3031.	0.6	5
276	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. <i>Blood</i> , 2010, 116, 37-37.	0.6	31
277	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010, 116, 3803-3803.	0.6	2
278	Phase I Study of Intravenous Plerixafor Added to a Mobilization Regimen of G-CSF In Lymphoma Patients Undergoing Autologous Stem Cell Collection. <i>Blood</i> , 2010, 116, 823-823.	0.6	1
279	A Phase I Study of PD 0332991: Complete CDK4/6 Inhibition and Tumor Response In Sequential Combination with Bortezomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2010, 116, 860-860.	0.6	5
280	Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 862-862.	0.6	5
281	Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 985-985.	0.6	12
282	Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study. <i>Blood</i> , 2010, 116, 986-986.	0.6	6
283	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. <i>Blood</i> , 2010, 116, 990-990.	0.6	5
284	Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib. <i>Blood</i> , 2010, 116, 1942-1942.	0.6	2
285	Germinal Center Specific Activation of K-Ras, Common In Multiple Myeloma, Is Selected Against and Is Not Sufficient to Initiate Plasma Cell Transformation In Mice. <i>Blood</i> , 2010, 116, 137-137.	0.6	0
286	Resequencing Analysis of the Human Candidate Ras and Receptor Tyrosine Kinase Gene Family In Multiple Myeloma. <i>Blood</i> , 2010, 116, 301-301.	0.6	0
287	Carfilzomib: High Single Agent Response Rate with Minimal Neuropathy Even In High-Risk Patients. <i>Blood</i> , 2010, 116, 1938-1938.	0.6	4
288	A Retrospective Review of Response to Donor Leukocyte Infusions In Adults with Acute Myeloid Leukemia After Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation.. <i>Blood</i> , 2010, 116, 4512-4512.	0.6	6

#	ARTICLE	IF	CITATIONS
289	Clofarabine: a size that fits all, may not fit all. <i>Leukemia and Lymphoma</i> , 2009, 50, 309-310.	0.6	0
290	An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. <i>American Journal of Hematology</i> , 2009, 84, 650-656.	2.0	94
291	Influence of Cytogenetics in Patients with Relapsed and Refractory Multiple Myeloma (MM) Treated with Carfilzomib (CFZ).. <i>Blood</i> , 2009, 114, 1827-1827.	0.6	2
292	Alkaline Phosphatase (ALP) Variation During Carfilzomib Treatment Is Associated to Best Response in Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2865-2865.	0.6	3
293	Updated Results of Bortezomib-Naïve Patients in PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM).. <i>Blood</i> , 2009, 114, 302-302.	0.6	6
294	PX-171-004, An Ongoing Open-Label, Phase II Study of Single-Agent Carfilzomib (CFZ) in Patients with Relapsed or Refractory Myeloma (MM); Updated Results From the Bortezomib-Treated Cohort.. <i>Blood</i> , 2009, 114, 303-303.	0.6	16
295	Prognostic Significance of PET Imaging in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Salvage Chemotherapy and Autologous Stem Cell Transplantation.. <i>Blood</i> , 2009, 114, 3417-3417.	0.6	1
296	Phase I Study of Carfilzomib in Patients (Pts) with Relapsed and Refractory Multiple Myeloma (MM) and Varying Degrees of Renal Insufficiency.. <i>Blood</i> , 2009, 114, 3877-3877.	0.6	6
297	Carfilzomib (CFZ), a Novel Proteasome Inhibitor for Relapsed or Refractory Multiple Myeloma, Is Associated with Minimal Peripheral Neuropathic Effects.. <i>Blood</i> , 2009, 114, 430-430.	0.6	11
298	Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.. <i>Blood</i> , 2009, 114, 432-432.	0.6	8
299	A Phase I/II Study of Chemosensitization with the CXCR4 Antagonist Plerixafor in Relapsed or Refractory AML.. <i>Blood</i> , 2009, 114, 787-787.	0.6	5
300	Alemtuzumab can be Incorporated Into Front-Line Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Phase I Results of a Cancer and Leukemia Group B Study (CALGB 10102).. <i>Blood</i> , 2009, 114, 838-838.	0.6	50
301	A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old.. <i>Blood</i> , 2009, 114, 842-842.	0.6	4
302	Waldenstrom's Macroglobulinemia: A SEER Database Review From 1981-2005.. <i>Blood</i> , 2009, 114, 2926-2926.	0.6	6
303	Busulfan/Fludarabine/Thymoglobulin as a Reduced Intensity Conditioning Regimen for Lymphoid Malignancies.. <i>Blood</i> , 2009, 114, 3335-3335.	0.6	0
304	Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1045-1056.	2.0	319
305	Mobilization and Chemosensitization of AML with the CXCR4 Antagonist Plerixafor (AMD3100): A Phase I/II Study of AMD3100+MEC in Patients with Relapsed or Refractory Disease.. <i>Blood</i> , 2008, 112, 1944-1944.	0.6	8
306	Initial Results of PX-171-003, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed and Refractory Multiple Myeloma (MM). <i>Blood</i> , 2008, 112, 864-864.	0.6	14

#	ARTICLE	IF	CITATIONS
307	Initial Results of PX-171-004, An Open-Label, Single-Arm, Phase II Study of Carfilzomib (CFZ) in Patients with Relapsed Myeloma (MM). <i>Blood</i> , 2008, 112, 865-865.	0.6	12
308	A Single-Institution Randomized Prospective Trial of Pre-Emptive Therapy with Oral Valganciclovir Compared with IV Ganciclovir for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplant (aHSCT), Delayed until Viral Load (VL) $\geq 10,000$ Copies/ml or $\geq 5,000$ Copies/ml X 2. <i>Blood</i> , 2008, 112, 4340-4340.	0.6	0
309	Prognostic Factors Influencing Survival in Solitary Plasmacytoma: A SEER Database Analysis.. <i>Blood</i> , 2008, 112, 1670-1670.	0.6	0
310	Azacitidine-Induced Changes in the MDS Methylome Are Associated with Clinical Responses. <i>Blood</i> , 2008, 112, 2691-2691.	0.6	0
311	Allogeneic Stem Cell Transplantation Conditioning for MDS and AML with Clofarabine, Cytarabine and ATG. <i>Blood</i> , 2008, 112, 4427-4427.	0.6	0
312	FLAG-IM (Fludarabine, Ara-C, G-CSF, Idarubicin, Mylotarg) Is an Effective Salvage Regimen Producing High Rates of Remission (CR+CRi) in Relapsed/Refractory AML.. <i>Blood</i> , 2007, 110, 1855-1855.	0.6	1
313	A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.. <i>Blood</i> , 2007, 110, 1451-1451.	0.6	1
314	Coordinate Interstitial Deletion of Retinoblastoma (RB1) and Neurobeachin (NBEA) Is a Recurring Event in Multiple Myeloma.. <i>Blood</i> , 2007, 110, 2480-2480.	0.6	0
315	Kinetics of Autologous Stem Cell Mobilization Failure: Comparison of AMD3100/G-CSF, G-CSF, GM-/G-CSF, and Chemotherapy/G-CSF on Remobilization Success.. <i>Blood</i> , 2006, 108, 3380-3380.	0.6	2
316	HLA-Matched Sibling Donor Stem Cell Mobilization Can Be Safely and Effectively Reduced from a Five Day to a One Day Process by a Direct Antagonist of the CXCR4/SDF-1 Interaction.. <i>Blood</i> , 2006, 108, 53-53.	0.6	7
317	Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Blood</i> , 2006, 108, 593-593.	0.6	3
318	Impact of Disease and Mobilizing Agents on Initial and Remobilization Failure.. <i>Blood</i> , 2006, 108, 5222-5222.	0.6	0
319	Bortezomib (Velcade) When Given Pretransplant and Once Weekly as Consolidation Therapy Following High Dose Chemotherapy (HDCT) Leads to High Rates of Reactivation of Varicella Zoster Virus (VZV).. <i>Blood</i> , 2005, 106, 3237-3237.	0.6	6
320	Once Weekly Bortezomib (Velcade) Preserves Bone Health by a Direct Effect on Osteoclast Function Independent of Its Effect on the Malignant Plasma Cells.. <i>Blood</i> , 2005, 106, 3458-3458.	0.6	1
321	Reduced Intensity Allografts for Acute Myeloid Leukemia: Defining the Role of Conditioning and Donor Alloreactivity.. <i>Blood</i> , 2004, 104, 5191-5191.	0.6	0
322	Once Daily Ganciclovir (ODG) as Initial Pre-Emptive Therapy (PT) Delayed until Threshold Viral Load $\geq 10,000$ Copies/ml: A Safe and Effective Strategy for Post-Allogeneic Stem Cell Transplant (ASCT) Patients.. <i>Blood</i> , 2004, 104, 3158-3158.	0.6	0
323	Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell transplantation. <i>Blood</i> , 2003, 101, 2067-2069.	0.6	34
324	Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. <i>Blood</i> , 2000, 95, 3605-3612.	0.6	69